Objective: To assess the efficacy and safety profile of docetaxel, as a single agent, in the treatment of elderly patients with advanced breast cancer. Methods: Twenty-eight patients, with a ...

CD47 expression may serve as a positive prognostic biomarker in metastatic NSCLC, correlating with better outcomes in patients treated with magrolimab plus docetaxel. Patients with metastatic ...

These agents have been successfully introduced into the treatment paradigms of a variety ... 2–14 of a 3-week cycle in combination with docetaxel (administered on day 1 in both cases).

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

We are working closely with the FDA to bring this additional [darolutamide] treatment option to patients as soon as possible.

The expansion in indications comes after the company’s Phase III trial saw the treatment extending survival in patients with ...

Jointly Bayer and Orion Corporation-developed NUBEQA (Darolutamide) + Androgen Deprivation Therapy (ADT) in combination with docetaxel is to be the first prostate cancer treatment to be made ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...

Bayer (BAYRY) announced that the FDA has accepted the company’s supplemental new drug application, or sNDA, for the oral androgen receptor ...

Novocure has refined the transducer arrays that attach to Optune Gio, its wearable for glioblastoma treatment.

ONCOLife proudly presents an exclusive interview with Dr. Iris Kuss, VP and Global Development Lead Oncology at Bayer. In ...